T
Thomas R. Einarson
Researcher at University of Toronto
Publications - 239
Citations - 16129
Thomas R. Einarson is an academic researcher from University of Toronto. The author has contributed to research in topics: Pregnancy & Randomized controlled trial. The author has an hindex of 61, co-authored 239 publications receiving 14632 citations. Previous affiliations of Thomas R. Einarson include Hospital for Sick Children.
Papers
More filters
Journal ArticleDOI
Prevalence of depression during pregnancy: systematic review.
TL;DR: Rates of depression, especially during the second and third trimesters of pregnancy, are substantial, and clinical and economic studies to estimate maternal and fetal consequences are needed.
Journal ArticleDOI
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017
TL;DR: CVD is a major cause of mortality among people with T2DM, accounting for approximately half of all deaths over the study period, and overall CVD affects approximately 32.2% of all persons with T 2DM.
Journal ArticleDOI
Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies
Laura Y. Park-Wyllie,Paolo Mazzotta,Anne Pastuszak,Myla E Moretti,Lizanne Beique,Laura Hunnisett,Mark H. Friesen,Sheila Jacobson,S. Kasapinovic,Debra Chang,Orna Diav-Citrin,David Chitayat,Irena Nulman,Thomas R. Einarson,Gideon Koren +14 more
TL;DR: Although prednisone does not represent a major teratogenic risk in humans at therapeutic doses, it does increase by an order of 3.4-fold the risk of oral cleft, which is consistent with the existing animal studies.
Journal ArticleDOI
Drug-Related Hospital Admissions
TL;DR: Drug-induced hospitalizations account for approximately five percent of all admissions, and should include the Third World and nonindustrialized nations as well as specific cultural groups.
Journal Article
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
Krista L. Lanctôt,Nathan Herrmann,Kenneth K. Yau,Lyla R. Khan,Barbara A. Liu,Maysoon M. LouLou,Thomas R. Einarson +6 more
TL;DR: A meta-analysis of randomized, double-blind, placebo-controlled, parallel-group trials of currently marketed ChEIs, used in therapeutic doses for at least 12 weeks, results in a modest but significant therapeutic effect and modestly but significantly higher rates of adverse events and discontinuation of treatment.